Keyphrases
Clinical Practice
100%
Heart Failure with Preserved Ejection Fraction (HFpEF)
100%
Taiwan Society of Cardiology
100%
Beta-blockers
60%
Angiotensin-converting Enzyme Inhibitor (ACEi)
60%
Angiotensin Receptor Blockers
60%
Mineralocorticoid Receptor Antagonists
60%
Target Dose
60%
Taiwan
40%
At Discharge
40%
Overprescription
40%
Heart Failure
20%
Western Countries
20%
Clinical Outcomes
20%
Mortality Rate
20%
Hospitalization
20%
1-year Follow-up
20%
Heart Failure Management
20%
Clinical Parameters
20%
Global Health Issue
20%
1-year Mortality
20%
Nonprescription Drugs
20%
Nonclinical
20%
Heart Failure Guidelines
20%
Physician Adherence
20%
Nursing and Health Professions
Clinical Practice
100%
Practice Guideline
100%
Heart Failure with Reduced Ejection Fraction
100%
Dipeptidyl Carboxypeptidase Inhibitor
42%
Congestive Heart Failure
42%
Angiotensin Receptor Antagonist
42%
Mineralocorticoid Antagonist
42%
Beta Adrenergic Receptor Blocking Agent
42%
Mortality Rate
14%
Clinical Outcome
14%
Protocol Compliance
14%
Diseases
14%
Medicine and Dentistry
Heart Failure with Reduced Ejection Fraction
100%
Cardiology
100%
Angiotensin Receptor Antagonist
60%
ACE Inhibitor
60%
Beta Adrenergic Receptor Blocking Agent
60%
Congestive Heart Failure
60%
Mineralocorticoid Antagonist
60%
Mortality Rate
20%
Protocol Compliance
20%
Diseases
20%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Failure with Reduced Ejection Fraction
100%
Dipeptidyl Carboxypeptidase Inhibitor
60%
Angiotensin Receptor Antagonist
60%
Congestive Heart Failure
60%
Beta Adrenergic Receptor Blocking Agent
60%
Mineralocorticoid Antagonist
60%
Mortality Rate
20%
Diseases
20%